EA202190089A1 - SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS - Google Patents
SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONSInfo
- Publication number
- EA202190089A1 EA202190089A1 EA202190089A EA202190089A EA202190089A1 EA 202190089 A1 EA202190089 A1 EA 202190089A1 EA 202190089 A EA202190089 A EA 202190089A EA 202190089 A EA202190089 A EA 202190089A EA 202190089 A1 EA202190089 A1 EA 202190089A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- antigen binding
- psma
- binding molecules
- bodies
- bispecific antigen
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Настоящее изобретение относится к биспецифичным антигенсвязывающим молекулам, содержащим первый антигенсвязывающий домен, который специфично связывает CD28 человека, и вторую антигенсвязывающую молекулу, которая специфично связывает PSMA человека. В отдельных вариантах осуществления биспецифичные антигенсвязывающие молекулы согласно настоящему изобретению способны ингибировать рост опухолей, экспрессирующих PSMA, таких как опухоли предстательной железы. Антитела и биспецифичные антигенсвязывающие молекулы согласно изобретению эффективны для лечения заболеваний и расстройств, при которых желателен и/или терапевтически эффективен повышенный или индуцированный нацеленный иммунный ответ.The present invention relates to bispecific antigen binding molecules comprising a first antigen binding domain that specifically binds human CD28 and a second antigen binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen binding molecules of the present invention are capable of inhibiting the growth of PSMA expressing tumors, such as prostate tumors. The antibodies and bispecific antigen binding molecules of the invention are effective in the treatment of diseases and disorders in which an increased or induced targeted immune response is desired and / or therapeutically effective.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962815878P | 2019-03-08 | 2019-03-08 | |
PCT/US2019/038460 WO2019246514A1 (en) | 2018-06-21 | 2019-06-21 | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190089A1 true EA202190089A1 (en) | 2021-03-22 |
Family
ID=75262254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA202190089A EA202190089A1 (en) | 2019-03-08 | 2019-06-21 | SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA202190089A1 (en) |
-
2019
- 2019-06-21 EA EA202190089A patent/EA202190089A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA202191580A1 (en) | SPECIFIC ANTI-CD28 X ANTI-CD22 ANTI-BODIES AND THEIR APPLICATION | |
PH12020552116A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
EA201890368A1 (en) | ANTIBODIES AGAINST PSMA, BISPECIFIC ANTIGENSELATING MOLECULES THAT BIND PSMA AND CD3 AND THEIR APPLICATION | |
EA201890785A1 (en) | OPTIMIZED BISPECIFIC ANTI-CD3 ANTIBODIES AND THEIR APPLICATION | |
EA201990781A1 (en) | ANTI-STEAP2 ANTIBODIES, CONJUGATES ANTIBODY MEDICINES AND BISSPECIFIC ANTIGEN BINDING MOLECULES THAT BIND STEAP2 AND CD3, AND THEIR APPLICATION | |
EA201590613A1 (en) | ANTIBODIES AGAINST CD3, BISPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO CD3 AND CD20, AND THEIR APPLICATIONS | |
EA201691858A1 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
EA202190315A1 (en) | CHIMERIC ANTIGENIC RECEPTORS SPECIFIC TO BCMA AND THEIR APPLICATION | |
EA201992402A1 (en) | ANTIBODIES AGAINST ILT4 AND ANTIGEN-BINDING FRAGMENTS | |
EA201491686A1 (en) | MULTISPECIFIC ANTIGEN-BINDING MOLECULES AND THEIR APPLICATIONS | |
BR112022009317A2 (en) | BIPARATOPIC CD73 ANTIBODIES | |
MX2021015271A (en) | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation. | |
EA202190089A1 (en) | SPECIFIC ANTI-PSMA X ANTI-CD28 ANTI-BODIES AND THEIR APPLICATIONS | |
EA202191677A1 (en) | SPECIFIC ANTI-MUC16 X ANTI-CD28 ANTI-BODIES AND VARIANTS OF THEIR APPLICATION | |
EA202190601A1 (en) | ANTI-Fc ANTIBODIES EPSILON-R1 ALPHA (FCER1A), BISPECIFIC ANTIGEN-BINDING MOLECULES BINDING FCΕR1Α AND CD3 AND THEIR APPLICATION | |
EA201991227A1 (en) | ANTIBODIES AGAINST CD3, SPECIFIC ANTIGEN-BINDING MOLECULES, WHICH BIND TO AND CD3 AND CD20 | |
EA202090303A3 (en) | ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS | |
EA202190314A1 (en) | BISPECIFIC ANTI-BCMA X ANTI-CD3 ANTIBODIES AND METHODS OF THEIR APPLICATION | |
EA202092279A1 (en) | ANTIBODIES TO MICA AND / OR MICB AND THEIR APPLICATION | |
EA202092672A1 (en) | ANTIBODIES AGAINST DLL3 AND THEIR APPLICATION | |
EA201992312A1 (en) | SPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF APPLICATION | |
EA201992324A1 (en) | ANTI-TREM2 ANTIBODIES AND WAYS OF THEIR APPLICATION | |
EA201990779A1 (en) | SPECIFIC ANTI-MUC16-CD3 ANTIBODIES AND CONJUGATES ANTI-MUC16-MEDICINE | |
EA202192306A3 (en) | POLYSPECIFIC ANTIGEN-BINDING MOLECULES AND THEIR APPLICATIONS |